Amendment to Schedule 13D Filing for Apogee Therapeutics, Inc.

This filing is an amendment to a previous Schedule 13D, originally filed on July 21, 2023. The amendment details changes in the beneficial ownership of Apogee Therapeutics, Inc. common stock. Fairmount Funds Management LLC, along with related entities and individuals (Peter Harwin and Tomas Kiselak), collectively hold voting and dispositive power over 6,666,332 shares of common stock, representing 9.84% of the class. This includes shares held directly and shares underlying vested options. Additionally, a lock-up agreement was entered into on March 26, 2026, in connection with a public offering, restricting the sale of securities for 60 days. The reporting persons did not purchase securities in this offering. The filing incorporates information from previous amendments and relevant exhibits.